Vu Kiem, Thompson George R, Roe Chandler C, Sykes Jane E, Dreibe Elizabeth M, Lockhart Shawn R, Meyer Wieland, Engelthaler David M, Gelli Angie
Department of Pharmacology, University of California, Davis, California, USA.
Department of Medical Microbiology and Immunology, University of California, Davis, California, USA.
Med Mycol. 2018 Oct 1;56(7):857-867. doi: 10.1093/mmy/myx135.
Cryptococcosis is an opportunistic fungal infection caused by members of the two sibling species complexes: Cryptococcus neoformans and Cryptococcus gattii. Flucytosine (5FC) is one of the most widely used antifungals against Cryptococcus spp., yet very few studies have looked at the molecular mechanisms responsible for 5FC resistance in this pathogen. In this study, we examined 11 C. gattii clinical isolates of the major molecular type VGIII based on differential 5FC susceptibility and asked whether there were genomic changes in the key genes involved in flucytosine metabolism. Susceptibility assays and sequencing analysis revealed an association between a point mutation in the cytosine deaminase gene (FCY1) and 5FC resistance in two of the studied 5FC resistant C. gattii VGIII clinical isolates, B9322 and JS5. This mutation results in the replacement of arginine for histidine at position 29 and occurs within a variable stretch of amino acids. Heterologous expression of FCY1 and spot sensitivity assays, however, demonstrated that this point mutation did not have any effect on FCY1 activities and was not responsible for 5FC resistance. Comparative sequence analysis further showed that no changes in the amino acid sequence and no genomic alterations were observed within 1 kb of the upstream and downstream sequences of either cytosine permeases (FCY2-4) or uracil phosphoribosyltransferase (FUR1) genes in 5FC resistant and 5FC susceptible C. gattii VGIII isolates. The herein obtained results suggest that the observed 5FC resistance in the isolates B9322 and JS5 is due to changes in unknown protein(s) or pathway(s) that regulate flucytosine metabolism.
新生隐球菌和格特隐球菌。氟胞嘧啶(5FC)是针对隐球菌属最广泛使用的抗真菌药物之一,但很少有研究探讨该病原体对5FC耐药的分子机制。在本研究中,我们基于对5FC的不同敏感性检测了11株主要分子类型为VGIII的格特隐球菌临床分离株,并询问参与氟胞嘧啶代谢的关键基因是否存在基因组变化。药敏试验和测序分析显示,在所研究的两株对5FC耐药的格特隐球菌VGIII临床分离株B9322和JS5中,胞嘧啶脱氨酶基因(FCY1)中的一个点突变与5FC耐药有关。该突变导致第29位的组氨酸被精氨酸取代,且发生在一段可变的氨基酸序列内。然而,FCY1的异源表达和点敏感性试验表明,该点突变对FCY1活性没有任何影响,也不是5FC耐药的原因。比较序列分析进一步表明,在对5FC耐药和敏感的格特隐球菌VGIII分离株中,胞嘧啶通透酶(FCY2 - 4)或尿嘧啶磷酸核糖转移酶(FUR1)基因的上游和下游1 kb序列内,未观察到氨基酸序列变化和基因组改变。本文获得的结果表明,在分离株B9322和JS5中观察到的5FC耐药是由于调节氟胞嘧啶代谢的未知蛋白质或途径的变化所致。